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Abstract
Background: Asthma was the most common co-morbidity among patients hospitalized with pandemic influenza A
(H1N1)pdm09 [pH1N1] infection. The objective was to compare characteristics of hospitalized pH1N1 patients with
and without asthma and assess factors associated with severity among asthma patients.
Methods: Patient data were derived from two 2009 pandemic case-series of U.S. pH1N1 hospitalizations. A case
was defined as a person ≥ 2 years old hospitalized with laboratory-confirmed pH1N1. Asthma status was
determined through chart review.
Results: Among 473 cases, 29% had asthma. Persons with asthma were more likely to be 2–17 years old (39% vs.
30%, p = 0.04) and black (29% vs. 18%, p < 0.01), and have chronic obstructive pulmonary disease (13% vs. 9%,
p = 0.04) but less likely to have pneumonia (37% vs. 47%, p = 0.05), need mechanical ventilation (13% vs. 23%,
p = 0.02), and die (4% vs. 10%, p = 0.04) than those without asthma. Among patients with asthma, those admitted
to an intensive care unit (ICU) or who died (n = 38) compared with survivors not admitted to an ICU (n = 99) were
more likely to have pneumonia on admission (60% vs. 27%, p < 0.01) or acute respiratory distress syndrome (24% vs.
0%, p < 0.01) and less likely to receive influenza antiviral agents ≤ 2 days of admission (73% vs. 92%, p = 0.02).
Conclusions: The majority of persons with asthma had an uncomplicated course; however, severe disease,
including ICU admission and death, occurred in asthma patients who presented with pneumonia. Influenza antiviral
agents should be started early in hospitalized patients with suspected influenza, including those with asthma.
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Background
Worldwide, annual influenza epidemics result in an
estimated 3–5 million cases of severe illness and 250,000-
500,000 deaths every year [1]. Globally, an estimated 300
million people suffer from asthma [2]. Asthma prevalence
varies widely between different countries ranging between
1 and 18% [3]. In 2009, the estimated asthma prevalence in
the United States was 8% [4]. Previous studies in the U.S.
have shown that asthma is common among patients
hospitalized with influenza. Among children younger than
18-years-old hospitalized with seasonal influenza from
2003 to 2008, 18% had asthma [5], and among adults aged
18–49 years hospitalized with seasonal influenza from
2005 to 2008, 27% had asthma [6]. In addition, during
the 2009 influenza A(H1N1)pdm09 [pH1N1] pandemic,
asthma was one of the most common underlying medical
conditions among patients hospitalized with pH1N1 infec-
tion in the U.S. [7-9] and worldwide [10-15]. In a global
pooled analysis looking at risk factors for severe outcomes
following pH1N1 infection, asthma was associated with
hospitalization and death, but among patients who were
hospitalized, those with asthma survived compared with
patients with other conditions [15]. Given the burden of
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asthma among patients hospitalized with pH1N1 infection
in the U.S., we sought to better understand patients with
asthma and in comparison with patients without asthma




We describe epidemiological and clinical characteristics
of patients with asthma hospitalized with pH1N1 infec-
tion in the U.S. during the spring and fall of 2009.
Patients
Patient data were obtained from two previously
described national pH1N1 hospitalizations case-series
conducted in the U.S. during the spring [7] and fall [8] of
2009. Patients included in these case-series had laboratory-
confirmed pH1N1 virus by real-time reverse-transcriptase
polymerase-chain-reaction; diagnostic testing for pH1N1
virus was clinically driven. In the spring (May 1-June 9,
2009), the first 272 hospitalized pH1N1 patients reported
to the Centers for Disease Control and Prevention (CDC)
were included; participation from 24 states yielded 25% of
the total number of cases reported during the spring
surveillance period [7]. In the fall (September 1-October
31, 2009), 255 hospitalized pH1N1 patients were sampled
from all cases reported based on probability of selection
proportional to the number of hospitalized cases reported
to CDC; participation from 40 states yielded < 2% of the
total number of cases reported to CDC during the fall sur-
veillance period [8].
Ethics statement
Both spring and fall case-series were part of the emer-
gency public health practice response to assess illness
severity during the 2009 pH1N1 pandemic and were
deemed not to be research in accordance with the fed-
eral human subjects protection regulations at 45 Code
of Federal Regulations 46.101c and 46.102d and CDC's
Guidelines for Defining Public Health Research and
Public Health Non-Research, and therefore were not
subject to Institutional Review Board (IRB) review and
approval; participation by the state and local health
departments was voluntary.
Study design
For this analysis, we excluded 54 children under two
years old because asthma is difficult to diagnose in this
age group [16,17]. Demographic and clinical information
was abstracted from medical charts by infection control
practitioners, physicians, nurses, or epidemiologists at
local and state public health departments using a stand-
ard clinical form and reported to the CDC.
Day of hospital admission was considered hospital day
0; for transfer patients, date of hospital admission related
to the first hospitalization was used. Asthma status was
determined by review of the admission history, problem
list, and discharge summary. If any of these areas of the
medical chart had a history of asthma listed, then the
patient was considered to have asthma. Pneumonia sta-
tus was based on admission chest radiograph reports.
Statistical analysis
We conducted bivariate analyses to compare characteristics
of patients with and without asthma and assessed factors
associated with intensive care unit (ICU) admission and
death among patients with asthma. We stratified all
categorical bivariate analyses by the age groups 2–9 years,
10–17 years, 18–49 years and ≥50 years and used either the
chi-square or Fisher’s Exact test to compare categorical
variables and the Wilcoxon rank-sum test to compare con-
tinuous variables (P ≤0.05). Data were analyzed using SAS
version 9.2 (SAS Institute, Cary, NC).
Results
Among 473 patients two years or older hospitalized with
pH1N1 infection in the two case-series, 137 (29%) had
asthma; this included 74/249 (30%) of spring and 63/224
(28%) of fall hospitalizations. Thirty-five per cent (54/
154) of children aged 2 to 17 years and 26% (83/319) of
adults aged 18 years or older had asthma. Patients with
asthma were significantly more likely than those without
asthma to be 2 to17 years old (39% versus 30%, p =
0.04), and to be black (29% versus 18%, p < 0.01)
(Table 1).
Patients with asthma were not more likely to be admit-
ted within 2 days of illness onset than patients without
asthma (54% versus 45%, p = 0.06); however, in the
10–17 year old age group, patients with asthma were
more likely to be admitted within 2 days of illness onset
(77% versus 51%, p = 0.03) (Table 2). Length of hospital
stay was similar between the two groups. Patients with
asthma were significantly more likely to present with
shortness of breath and wheezing than those without
asthma. Patients with asthma were significantly more
likely to have chronic obstructive pulmonary disease
(COPD) (13% versus 9%, p = 0.04) and were less likely to
have chronic renal disease (2% versus 11%, p < 0.01) than
patients without asthma. Of the patients with asthma
who also had COPD, 9/16 (56%) were current smokers;
former smoking status was not available. Patients with
asthma were less likely than those without asthma to
have radiographic findings consistent with pneumonia
(37% versus 47%, p = 0.05). There was no statistical
difference in positive sterile site bacterial culture (1%
versus 4%, p = 0.11) confirmed by admission blood
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culture, sterile respiratory site culture, or urine antigen
test between the two groups.
There were no significant differences in the proportion
of ICU admission (28% versus 34%) or diagnosis of acute
respiratory distress syndrome (ARDS) (7% versus 13%)
between the two groups (Table 3). However, patients
with asthma compared with patients without asthma
were significantly less likely to require invasive mechan-
ical ventilation (13% versus 23%, p = 0.02) and to die
while hospitalized (4% versus 10%, p = 0.04).
Overall, hospitalized patients with and without asthma
were equally likely to receive influenza antiviral agents
(74% versus 80%) (Table 3). There was also no signifi-
cant difference between the two groups in receipt of
antiviral agents within 2 days of illness onset (50% versus
39%) or within 2 days of admission (86% versus 87%).
However, among 72 patients 10–17 years old, patients
with asthma were more likely than patients without
asthma to receive antiviral agents within 2 days of illness
onset (89% versus 38%, p < 0.01) and within 2 days of ad-
mission (100% versus 76%, p = 0.03). Patients with
asthma were significantly more likely than those without
asthma to receive oral or intravenous steroids (61% ver-
sus 29%, p < 0.01).
Among patients hospitalized with pH1N1 infection
who had asthma, those admitted to an ICU or who died
(n = 38) compared with survivors not admitted to an
ICU (n = 99) were significantly more likely to present
with tachypnea, have pneumonia, ARDS, and a longer
Table 1 Demographic characteristics: comparison of










Female 81 (59) 175/334 (52) 0.07
Median age in years (range) 27 (3 – 80) 30 (2 – 87) 0.15
Age 2–17 years 54 (39) 100 (30) 0.04
Age group 0.08
2–9 years 28 (20) 54 (16) 0.26
10–17 years 26 (19) 46 (14) 0.15
18–49 years 58 (42) 160 (48) 0.30
≥50 years 25(18) 76 (23) 0.29
Race and ethnicity 0.17
Non-Hispanic White 47 (34) 137 (41) 0.19
Black 40 (29) 60 (18) <0.01
Hispanic 28 (20) 78 (23) 0.51
Unspecified 15 (11) 40 (12) 0.77
Other† 7 (4) 18 (5) 0.91
*P-Values stratified by age-group.
†Other race and ethnicity includes Asian, Native Hawaiian or Pacific Islander,
American Indian or Alaska Native and Multiracial.
Table 2 Clinical characteristics: comparison of patients










Median days from onset to
admission (range)
2 (0 – 20)
(n = 136)
3 (0 – 21)
(n = 332)
0.06
Admission within 2 days of
illness onset
74/136 (54) 150/334 (45) 0.06
Median length of stay- days
(range)
3 (0 – 47)
(n = 136)





Cough 118 (86) 284 (85) 0.45
Fever 115 (84) 294 (88) 0.20
Shortness of Breath 91 (66) 155 (46) <0.01
Wheezing 62 (45) 47 (14) <0.01
Fatigue/Weakness 47 (34) 125 (37) 0.71
Myalgias 43 (31) 122 (36) 0.57
Rhinorrhea 42 (31) 103 (31) 0.88
Chills 38 (28) 120 (36) 0.23
Sore Throat 33 (24) 96 (29) 0.25
Vomiting 31 (23) 98 (29) 0.08
Headache 31 (23) 99 (30) 0.17





64 (47) 217 (50) 0.11
Diabetes 24 (18) 51 (15) 0.18
Chronic obstructive
pulmonary disease
18 (13) 31 (9) 0.04
Cardiovascular disease 16 (12) 52 (16) 0.55
Immunosuppression 15 (11) 48 (14) 0.45
Neuromuscular disorder 11 (8) 26 (8) 0.87
Cognitive dysfunction 10 (7) 25 (7) 0.76
Seizure disorder 7 (5) 25 (7) 0.21
Chronic renal disease 3 (2) 38 (11) <0.01
Pregnancy 8 (6) 38 (12) 0.11
Current smoker 23/121 (19) 58/303 (19) 0.56
Obese or morbidly obese† 47/129 (36) 103/298 (35) 0.37
Positive sterile site culture 1/137 (1) 13/336 (4) 0.11
Pneumonia at admission 45/123 (37) 133/281 (47) 0.05
Seasonal flu vaccine 33/86 (38) 64/203 (32) 0.49
*P-Values stratified by age-group.
†Body-Mass Index (BMI) was calculated for a subset of patients for whom
height and weight were available to determine obesity (BMI 30–39.9 in adults
≥18 years or BMI percentile 95–100 in children 2 to 19 years old) and morbid
obesity (BMI ≥40 in adults only); pregnant women were excluded from
this calculation.
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median length of hospital stay (6 days versus 2 days)
(Table 4). Patients with asthma who were admitted to an
ICU or died compared with survivors who were not ad-
mitted to an ICU were equally likely to have an under-
lying medical condition other than asthma. Patients with
asthma who were admitted to an ICU or died were
equally likely to receive antiviral agents compared with
survivors who were not admitted to an ICU, including
within 2 days of illness onset, but were significantly less
likely to receive antiviral agents within 2 days of admis-
sion (73% versus 92%, p = 0.02).
Discussion
Among a national case-series of patients hospitalized
with pH1N1 infection in the U.S., during both waves of
the pH1N1 pandemic, almost one in every three patients
hospitalized with pH1N1 virus infection two years or
older had asthma. The majority of hospitalized persons
with asthma and pH1N1 infection had an uncomplicated
hospital course with less pneumonia upon admission,
need for mechanical ventilation and death in this group
compared with those without asthma. However, almost
40% of the patients hospitalized with pH1N1 infection
with asthma had pneumonia upon admission, and these
patients were more likely to require ICU admission or
die than patients with asthma who did not have pneu-
monia upon admission. Data from this analysis suggest
that early treatment with influenza antiviral agents
within 2 days of admission may be beneficial in reducing
illness severity in patients with asthma.
In our analysis, the proportion of children (35%) and
adults (26%) with asthma who were hospitalized with
pH1N1 infection was notably higher than the national
prevalence of asthma among children (9.6%) and adults
(7.7%) in the U.S. [17]. These data are consistent with
both seasonal and pandemic influenza U.S. reports dem-
onstrating similar proportions of asthma among patients
hospitalized with influenza. From 2005–2008, among
adults (n = 1267) hospitalized with seasonal influenza,
27% of adults aged 18–49 years had asthma [6]. In a re-
cent national multi-center study that included 2,165
children aged 2–17 years old hospitalized with influenza
from 2003 to 2009, 32% had asthma, with a higher
proportion (44%) during the 2009 pH1N1 pandemic
compared with previous seasons [18]. Data from inter-
national studies reported similar proportions of asthma
among hospitalized patients with pH1N1 infection in-
cluding reports from Australia (31%), Ireland (18%),
Singapore (19%), Spain (23%), and the United Kingdom
(25%) [10-14].
In our age group stratified analysis, patients with
asthma were more likely to have COPD than patients
without asthma. As over 20% of the patients in our case-
series were 50 years or older and there is an overlap in
asthma and COPD obstructive pathophysiology in the
airways [19], this is not an unexpected finding. As per-
sons with asthma age, the airway obstruction becomes
less reversible due to airway remodeling from chronic
inflammation and fibrosis leading to a more chronic
obstructive pathology that retains features of asthma
[20]. The elderly may have asthma alone, COPD alone,
or both; diagnosing either asthma or COPD alone may
be challenging, in part because these patients may not
be regularly monitored with spirometry to document
progression of their obstructive disease [21]. In addition,
almost 60% of patients with asthma and COPD were
current smokers, which likely contributed to their dual
co-morbidities.
Approximately 30% of patients with and without
asthma in our analysis were admitted to the ICU, but
overall the majority of patients with asthma had an un-
complicated hospital course, including less mechanical
ventilation and death compared with those without
asthma. The reasons for this are unclear. Patients
included in our analysis may have been admitted to an
ICU more readily if they had a history of asthma as a
precaution and not due to the severity of their present
illness; this would bias our analysis to demonstrating less
Table 3 Clinical characteristics and outcomes: comparison










Tachypnea 60/137 (44) 110/336 (33) 0.07
Tachycardia 88/137 (64) 213/336 (63) 0.86
Intensive care unit
admission
37/133 (28) 108/321 (34) 0.31
Mechanical ventilation 16/127 (13) 69/301 (23) 0.02
Acute respiratory distress
syndrome
9/129 (7) 38/292 (13) 0.10
Sepsis syndrome 7/128 (6) 31/291 (11) 0.12





101/137 (74) 270/336 (80) 0.15
≤ 2 days of illness onset 49/99 (50) 106/269 (39) 0.10
≤ 2 days of admission 79/92 (86) 219/253 (87) 0.87
Median days from illness
onset to antiviral
initiation (range)
3 (0 – 18) 3 (0 – 32) 0.06
Other treatment
Antibiotics 101/137 (74) 260/336 (77) 0.40
Steroids 83/137 (61) 96/336 (29) <0.01
*P-Values stratified by age-group.
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severe outcomes in this group. Other reports which also
used chart review to determine presence of asthma have
reported similar findings. In a recent national multi-
center study that included 1,434 children aged 2–17 years
old with asthma who were hospitalized with seasonal and
pandemic influenza from 2003 to 2009, 14–24% were
admitted to the ICU but only 2–11% had respiratory fail-
ure and < 1% of these patients required extracorporeal
membrane oxygenation or died [18]. In a California
pH1N1 case-series that included 1,088 adults and chil-
dren, 24% of patients had asthma but fewer deaths
occurred in those with asthma than those without asthma
(7% versus 12%) [9]. In a global pooled analysis of patients
hospitalized with pH1N1 infection that included asthma
data from 11 countries, while asthma was the most com-
mon underlying condition associated with hospitalization,
a higher proportion of patients with asthma survived
compared with patients with other conditions [15]. When
looking at country specific data, this also holds true,
including in one of the largest studied cohorts in the
United Kingdom where asthma was the most common
underlying condition among 1520 hospitalized pH1N1
patients but had a significant lower odds of death [22].
Patients with asthma in our analysis were also less
likely to have a diagnosis of pneumonia upon admission
than patients without asthma. Our study results are in
contrast with a recent national multi-center study of
2,992 children under 18 years old hospitalized with sea-
sonal influenza from 2003 to 2008 who had a chest
radiograph performed, in which patients with asthma
were more likely than those without asthma to have
pneumonia (41% versus 34%, p < 0.01) [23]. This study
differed from our analysis in the following ways: it
examined seasonal not pandemic influenza, included
only children, and permitted the chest radiograph to be
performed anytime during hospitalization as opposed to
at admission as is used for our analysis. These study de-
sign differences could help explain the different findings
Table 4 Characteristics for ICU admission and death among patients with asthma hospitalized with 2009 Pandemic
Influenza A (H1N1) Infection: comparison of patients with asthma admitted to an ICU or who died versus patients with
asthma who were not admitted to an ICU and survived (n = 137)
Characteristic Intensive care unit or deaths Non-intensive care unit survivors P-Value*
No. (%) (n = 38) No. (%) (n = 99)
Median days from onset to admission (range) 2 (0 – 15) 2 (0 – 20) 0.52
Admission within 2 days of illness onset 20 (53) 54 (55) 0.80
Median length of stay- days (range) 6 (0 – 47) 2 (1 – 10) <0.01
Age 2–17 years old 12/38 (32) 42/99 (42) 0.24
Underlying medical condition excluding asthma 20 (53) 44 (44) 0.39
Pregnancy 3 (8) 5 (5) 0.83
Current smoker 7 (22) 16 (18) 0.82
Obese or morbidly obese† 8/29 (28) 21/69 (30) 0.29
Tachypnea 23/38 (61) 37/99 (37) <0.01
Tachycardia 28/38 (74) 60/99 (60) 0.12
Mechanical ventilation 16/38 (42) 0/99 (0) <0.01
Acute respiratory distress syndrome 9/38 (24) 0/99 (0) <0.01
Sepsis syndrome 6/38 (16) 0/99 (0) <0.01
Pneumonia at admission 22/37 (60) 23/86 (27) <0.01
Seasonal flu vaccination 8/25 (32) 23/29 (39) 0.45
Influenza antiviral agent receipt
Any during hospitalization 32/38 (84) 68/99 (69) 0.07
≤2 days of illness onset 13/32 (41) 36/66 (55) 0.14
≤2 days of admission 22/30 (73) 57/62 (92) 0.02
Median days from illness onset to antiviral initiation (range) 3 (0 – 15) 2 (0 – 15) 0.15
Other treatment
Antibiotics 35/38 (92) 64/99 (65) <0.01
Steroids 25/38 (66) 58/99 (59) 0.45
*P-Values stratified by age-group.
†Body-Mass Index (BMI) was calculated for a subset of patients for whom height and weight were available to determine obesity (BMI 30–39.9 in adults ≥18 years
or BMI percentile 95–100 in children 2 to 18 years old) and morbid obesity (BMI ≥40 in adults only); pregnant women were excluded from this calculation.
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between these two studies. However, it is important to
note that in both studies, almost 40% of patients with
asthma had pneumonia. Pneumonia is a known compli-
cation of influenza [24,25] and is an important cause of
morbidity during seasonal and pandemic influenza
periods [5,23]. Further clarity on the relationship be-
tween asthma and influenza-associated pneumonia is
needed to better understand which persons with asthma
are at greater risk for pneumonia.
The majority of patients in our analysis received influ-
enza antiviral agents with no significant differences
among those with and without asthma, including in rela-
tion to illness onset or admission time; in addition there
was no significant difference in time from illness onset
to admission between the two groups. However, only
50% of patients with asthma received antiviral agents
within 2 days of illness onset. It is unclear if delayed
treatment was due to delay in testing, delayed ascertain-
ment of results, or antiviral agent clinical prescribing
practice. When looking at factors associated with ICU
admission or death, early antiviral treatment in relation to
hospital admission was found to be protective among those
with asthma. This adds to the existing evidence underscor-
ing the importance of early influenza treatment among
those persons with suspected or confirmed influenza infec-
tion who are hospitalized and those with underlying med-
ical conditions, including asthma, regardless of their prior
vaccination status as is recommended by the Advisory
Committee on Immunization Practices (ACIP) [26].
Our data are subject to limitations. The patients
described in this analysis were derived from two
hospitalization case-series that used different sampling
methods [7,8]. However, data from both periods were
nationally representative of hospitalizations from areas
in the U. S. where peak disease activity was occurring at
the time. Patients included in this analysis were
confirmed for pH1N1 virus and may not be representa-
tive of hospitalized patients who may not have been
tested. Despite use of a standard data collection form,
not all information was collected for all patients, includ-
ing influenza vaccination status (pH1N1 vaccine was not
readily available during the study); this limits our ability
to assess these interventions, however the study was not
designed to address these specific questions. In addition
diagnoses of asthma and ARDS were ascertained from
history and clinical diagnosis and not by a standardized
clinical assessment. We were also not able to deter-
mine the level of baseline severity of asthma among
patients described in this cases-series, including past
hospitalizations, intubations, and steroid or inhaler use,
which could help explain which persons with asthma are
at risk for more severe outcomes. Patients with asthma
may have been misclassified as having COPD or vice
versa.
Conclusions
Among patients hospitalized with pH1N1 virus infection
in 2009, asthma was the most common underlying med-
ical condition. While most patients with asthma had an
uncomplicated course of illness, severe disease, including
ICU admission and death, still occurred, especially in
those who had pneumonia on admission. Since 1964,
persons with asthma have been prioritized for influenza
vaccination by the ACIP; however, they remain under-
immunized with less than 30% influenza vaccine coverage
in this group [27]. Vaccine is the primary tool for preven-
tion of influenza infection and should continue to be
encouraged in patients with asthma. This study also
suggests that early antiviral therapy can reduce influenza-
associated complications, and should be started as early as
possible in all hospitalized patients and in outpatients with
high-risk conditions, including those with asthma.
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